Background: Guillain-Barré syndrome (GBS) is an acute polyneuropathy caused by an autoimmune response towards a foreign antigen, notably viral infections. It is characterised by a symmetrical ascending paralysis with treatment remaining largely supportive; however, plasma exchange or intravenous immunoglobulins can be used to shorten recovery time. Case Report: We describe a case of severe acute GBS in a patient post-renal transplantation. The 44-year-old gentleman's induction therapy consisted of methyl prednisolone and basiliximab, with subsequent tacrolimus and mycophenolate mofetil as immunosuppressive agents. Tacrolimus was discontinued immediately on suspicion of a temporal relationship with the patient's condition, and substituted with a combination of ciclosporin, mycophenolate mofetil and prednisolone. Due to extensive patient screening prior to transplant, negative virology/immunology and normal nerve biopsy findings, both tacrolimus and basiliximab may be indicated as causative agents. Conclusion: Immunosuppressive-induced GBS should be considered a differential diagnosis in patients on tacrolimus or basiliximab with acute-onset limb weakness, especially if recently commenced. Discontinuation of tacrolimus and initiation of plasma exchange for the treatment for tacrolimus-associated GBS may be beneficial.

Keywords:
Guillain-Barré syndrome, Renal transplant, Tacrolimus, Basiliximab
1.
Hughes RA, Hadden RD, Gregson NA, et al: Pathogenesis of Guillain-Barré syndrome. J Neuroimmunol 1999;100:74-97.
2.
Hughes RA, Cornblath DR: Guillain-Barré syndrome. Lancet 2005;366:1653-1666.
3.
J B Winer: Guillain Barré syndrome. Mol Pathol 2001;54:381-385.
4.
Cortese I, Chaudhry V, So YT, et al: Evidence-based guideline update: plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2011;76:294-300.
5.
Webster AC, Taylor RRS, Chapman JR, et al: Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 2005;4:CD003961.
6.
Maccario M, Tarantino A, Nobile-Orazio E, Ponticelli C: Campylobacter jejuni bacteremia and Guillain-Barré syndrome in a renal transplant recipient. Transpl Int 1998;11:439-442.
7.
McMaster P, Mirza DF, Ismail T, et al: Therapeutic drug monitoring of tacrolimus in clinical transplantation. Ther Drug Monit 1995;17:602-605.
8.
Wilson JR, Conwit RA, Eidelman BH, et al: Sensorimotor neuropathy resembling CIDP in patients receiving FK506. Muscle Nerve 1994;17:528-532.
9.
Bhagavati S, Maccabee P, Muntean E, et al: Chronic sensorimotor polyneuropathy associated with tacrolimus immunosuppression in renal transplant patients: case reports. Transplant Proc 2007;39:3465-3467.
10.
Hunt I: Cyclosporine not the only agent to cause Guillain-Barré-like syndrome after solid-organ transplant. J Heart Lung Transplant 2006;25:1387.
11.
Falk JA, Cordova FC, Popescu A, et al: Treatment of Guillain-Barré syndrome induced by cyclosporine in a lung transplant patient. J Heart Lung Transplant 2006;25:140-143.
12.
Hartung HP, Hughes RA, Taylor WA, Heininger K, Reiners K, Toyka KV: T cell activation in Guillain-Barré syndrome and in MS: elevated serum levels of soluble IL-2 receptors. Neurology 1990;40:215-218.
13.
Qureshi AI, Cook AA, Mishu HP, Krendel DA: Guillain-Barré syndrome in immunocompromised patients: a report of three patients and review of literature. Muscle Nerve 1997:20:1002-1007.
14.
Kaya B, Davies CE, Oakervee HE, et al: Guillain-Barré syndrome precipitated by the use of antilymphocyte globulin in the treatment of severe aplastic anaemia. J Clin Pathol 2005;58:994-995.
15.
Gensicke H, Datta AN, Dill P, et al: Increased incidence of Guillain-Barré syndrome after surgery. Eur J Neurol 2012;19:1239-1244.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.